Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer

Siegel R. , Naishadham D. , Jemal A. . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1): 10–29

National Institutes of Health. Cancer of the Lung and Bronchus — SEER Stat Facts Sheet. 2012. http://seer.cancer.gov/statfacts/html/lungb.html. Accessed July 19, 2012.

Jackman D.M. , Miller V.A. , Cioffredi L.A. . Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009; 15(16): 5267–5273.

Wu Y.L. , Park K. , Soo R.A. . INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer. 2011; 11: 430.

Tyagi P. , Mirakhur B. . MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer. 2009; 10(5): 371–374.

Quoix E. , Ramlau R. , Westeel V. . Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 2011; 12(12): 1125–1133.

Hayes T.G. , Falchook G.F. , Varadhachary G.R. . Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs. 2006; 24(3): 233–240.

Nemunaitis J. , Dillman R.O. , Schwarzenberger P.O. . Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006; 24(29): 4721–4730.

Kantoff P.W. , Higano C.S. , Shore N.D. . Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5): 411–422.

Brahmer J.R. , Tykodi S.S. , Chow L.Q. . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26): 2455–2465.

Lynch T.J. , Bondarenko I. , Luft A. . Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; 30(17): 2046–2054.

Topalian S.L. , Hodi F.S. , Brahmer J.R. . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26): 2443–2454.

Digumarti R. , Wang Y. , Raman G. . A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol. 2011; 6(6): 1098–1103.

Butts C. , Murray N. , Maksymiuk A. . Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005; 23(27): 6674–6681.

Butts C. , Maksymiuk A. , Goss G. . Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol. 2011; 137(9): 1337–1342.

Ramlau R. , Quoix E. , Rolski J. . A phase II study of Tg4010 (Mva-Muc1-IL2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol. 2008; 3(7): 735–744.

Neninger Vinageras E. , de la Torre A. , Osorio Rodríguez M. . Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol. 2008; 26(9): 1452–1458.

Vansteenkiste J. , Zielinski M. , Linder A. . Final results of a multicenter, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2007; 25(18 suppl): 7554.

Varadhachary A. , Wolf J.S. , Petrak K. . Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer. 2004; 111(3): 398–403.

Hirsh V. , Paz-Ares L. , Boyer M. . Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29(19): 2667–2674.

Ho S.B. , Niehans G.A. , Lyftogt C. . Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993; 53(3): 641–651.

Regimbald L.H. , Pilarski L.M. , Longenecker B.M. . The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 1996; 56(18): 4244–4249.

Burchell J. , Gendler S. , Taylor-Papadimitriou J. . Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987; 47(20): 5476–5482.

Samuel J. , Budzynski W.A. , Reddish M.A. . Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int J Cancer. 1998; 75(2): 295–302.

Palmer M. , Parker J. , Modi S. . Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer. 2001; 3(1): 49–58.

Trevor K.T. , Hersh E.M. , Brailey J. . Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol Immunother. 2001; 50(8): 397–407.

Cohen S. , Kaufman H.L. . TG-4010 Transgene. Curr Opin Invest Drugs. 2004; 5(12): 1319–1328.

Rochlitz C. , Figlin R. , Squiban P. . Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med. 2003; 5(8): 690–699.

Shepherd F.A. , Rodrigues Pereira J. , Ciuleanu T. . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2): 123–132.

Mok T.S. , Wu Y.L. , Thongprasert S. . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10): 947–957.

Gonzalez G. , Crombet T. , Torres F. . Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol. 2003; 14(3): 461–466.

Ramos T.C. , Vinageras E.N. , Ferrer M.C. . Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a phase I trial. Cancer Biol Ther. 2006; 5(2): 145–149.

Rodriguez P.C. , Neninger E. , García B. . Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an epidermal growth factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients. J Immune Based Ther Vaccines. 2011; 9: 7.

Marchand M. , van Baren N. , Weynants P. . Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999; 80(2): 219–230.

Nemunaitis J. , Jahan T. , Ross H. . Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 2006; 13(6): 555–562.

Kong F. , Jirtle R.L. , Huang D.H. . Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer. 1999; 86(9): 1712–1719.

Parikh P.M. , Vaid A. , Advani S.H. . Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol. 2011; 29(31): 4129–4136.

Phan G.Q. , Yang J.C. , Sherry R.M. . Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003; 100(14): 8372–8377.

Hodi F.S. , O'Day S.J. , McDermott D.F. . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8): 711–723.

Robert C. , Thomas L. , Bondarenko I. . Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26): 2517–2526.

Topalian S.L. , Drake C.G. , Pardoll D.M. . Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012; 24(2): 207–212.

Okazaki T. , Honjo T. . PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007; 19(7): 813–824.

Dessureault S. , Noyes D. , Lee D. . A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol. 2007; 14(2): 869–884.

Govindan R. , Page N. , Morgensztern D. . Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24(28): 4539–4544.

Grant S.C. , Kris M.G. , Houghton A.N. . Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clin Cancer Res. 1999; 5(6): 1319–1323.

Giaccone G. , Debruyne C. , Felip E. . Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol. 2005; 23(28): 6854–6864.

Chiappori A.A. , Soliman H. , Janssen W.E. . INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010; 10(6): 983–991.

Fuentes R. , Allman R. , Mason M.D. . Ganglioside expression in lung cancer cell lines. Lung Cancer. 1997; 18(1): 21–33.

McCaffery M. , Yao T.J. , Williams L. . Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res. 1996; 2(4): 679–686.

Nikitina E.Y. , Chada S. , Muro-Cacho C. . An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther. 2002; 9(5): 345–352.